New York, NY June, 15 2006 – Daxor Corporation (AMEX:DXR), a medical instrumentation and biotechnology company, today announced that at their Annual Shareholders Meeting held on Wednesday, June 14, 2006 at their New York City headquarters, in addition to the re-election of the present six Board of Directors, Mr. Robert G. Moussa was elected to the Board as an additional Director.
Mr. Moussa worked for Mallinckrodt, a $2.4 billion healthcare and chemistry company, from 1978 to 1997. He served as Vice President and General Manager – Medical Products Europe, and rose to the position of President and CEO of Mallinckrodt Medical, a $1.1 billion company. The company was acquired by Tyco in 1998. Since 1997 Mr. Moussa has been President of Robert Moussa and Associates, an international healthcare consulting company.
Dr. Joseph Feldschuh, Daxor’s CEO, stated that, “Mr. Moussa brings an unusual background and expertise on the international market for medical diagnostic products, including radio-pharmaceuticals which are part of Daxor’s product specialty. In addition to his input as a Director, Mr. Moussa will be assisting the Company in a consulting capacity for domestic and international development of the BVA-100 Blood Volume Analyzer and the Blood Bank.”
Daxor has also appointed Everis Engstrom to succeed Ron Baldry as Vice President of Engineering. Mr. Baldry has worked for Daxor since 1985 and will continue as a consultant in R&D. Engstrom joins Daxor with over 25 years of product development and operations management experience in the medical device industry
During 8 years with Beckman Coulter, Mr. Engstrom was responsible for small hematology system development, leading the development of the Ac*T series of low cost hematology analyzers. Previously he was with Bayer Diagnostics fort for 16 years in various positions, including project manager for the first four generations of the GLUCOMETER blood glucose monitors, manager of product engineering, and manager of manufacturing.
Stephen Feldschuh, CFO & VP of Operations stated that, “These are very significant changes for the future of Daxor. We have added direction from both the director level and the engineering level from two individuals who have decades of industry experience and who will help Daxor achieve the goal of Standard of Care for the BVA-100 Blood Volume Analyzer.”
Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with a single use diagnostic kit, and measures blood volume to within a 98% accuracy. For more information regarding Daxor Corporation’s Blood Volume Analyzer BVA-100, visit Daxor’s website www.Daxor.com.